Regulation S-K

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Friday, July 10, 2020 - 3:03pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Friday, July 10, 2020 - 3:03pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Thursday, July 9, 2020 - 3:09pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Thursday, July 9, 2020 - 3:09pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Novelion Therapeutics Ceases to be a Reporting Issuer in Canada

Wednesday, July 8, 2020 - 8:17pm

The order was issued in response to an application made by Novelion and accordingly, Novelion will no longer be required to file financial statements or other continuous disclosure documents with Canadian securities regulatory authorities.

Key Points: 
  • The order was issued in response to an application made by Novelion and accordingly, Novelion will no longer be required to file financial statements or other continuous disclosure documents with Canadian securities regulatory authorities.
  • Novelion does not intend to file any financial statements or any periodic or other reports or filings with the Commission, except for the aforementioned current reports.
  • The impact from any such risks and uncertainties could materially reduce or eliminate the availability of assets available for distribution to shareholders.
  • Novelion cautions investors and others not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

GOGL - 2020 Annual General Meeting

Wednesday, July 8, 2020 - 7:36pm

Golden Ocean Group Limited (the Company) advises that the 2020 Annual General Meeting of the Company will be held on August 31, 2020.

Key Points: 
  • Golden Ocean Group Limited (the Company) advises that the 2020 Annual General Meeting of the Company will be held on August 31, 2020.
  • The record date for voting at the Annual General Meeting is set to July 17, 2020.
  • The notice, agenda and associated material will be distributed prior to the meeting.
  • This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

FRO - 2020 Annual General Meeting

Wednesday, July 8, 2020 - 6:18pm

Frontline Ltd. (the Company) advises that the 2020 Annual General Meeting of the Company will be held on August 31, 2020.

Key Points: 
  • Frontline Ltd. (the Company) advises that the 2020 Annual General Meeting of the Company will be held on August 31, 2020.
  • The record date for voting at the Annual General Meeting is set to July 17, 2020.
  • The notice, agenda and associated material will be distributed prior to the meeting.
  • This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Wednesday, July 8, 2020 - 6:07pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Wednesday, July 8, 2020 - 6:06pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Monday, July 6, 2020 - 3:04pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.